🇺🇸 LY293111 in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 10

Most-reported reactions

1. Activated Partial Thromboplastin Time Prolonged — 1 report (10%)
2. Activated Partial Thromboplastin Time Shortened — 1 report (10%)
3. Acute Prerenal Failure — 1 report (10%)
4. Anaemia — 1 report (10%)
5. Ascites — 1 report (10%)
6. Asthenia — 1 report (10%)
7. Blood Pressure Immeasurable — 1 report (10%)
8. Blood Pressure Systolic Increased — 1 report (10%)
9. Cholelithiasis — 1 report (10%)
10. Clostridium Colitis — 1 report (10%)

Source database →

Frequently asked questions

Is LY293111 approved in United States?

LY293111 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for LY293111 in United States?

Eli Lilly and Company is the originator. The local marketing authorisation holder may differ — check the official source linked above.